Arcutis Biotherapeutics, Inc. Common Stock Earnings Dividend

Arcutis Biotherapeutics, Inc. Common Stock’s revenue jumped 59.33% since last year same period to $129.86Mn in the Q2 2026. On a quarterly growth basis, Arcutis Biotherapeutics, Inc. Common Stock has generated 23.21% jump in its revenue since last 3-months.

Arcutis Biotherapeutics, Inc. Common Stock’s net profit jumped 194.48% since last year same period to $15.01Mn in the Q2 2026. On a quarterly growth basis, Arcutis Biotherapeutics, Inc. Common Stock has generated 232.88% jump in its net profits since last 3-months.

Arcutis Biotherapeutics, Inc. Common Stock’s net profit margin jumped 159.3% since last year same period to 11.56% in the Q2 2026. On a quarterly growth basis, Arcutis Biotherapeutics, Inc. Common Stock has generated 207.85% jump in its net profit margins since last 3-months.

Arcutis Biotherapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at 0.17 - a 88.89% jump from last quarter’s estimates.

Arcutis Biotherapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at 0.17.

Arcutis Biotherapeutics, Inc. Common Stock’s earning per share (EPS) jumped 184.62% since last year same period to 0.11 in the Q2 2026. This indicates that the Arcutis Biotherapeutics, Inc. Common Stock has generated 184.62% annual rate of jump in its earning per share (EPS) in the last 4 quarters.